Found vs IVIM Health vs SkinnyRx (2026)
On tirzepatide, the order is IVIM Health↗ ($278) → Found ($289) → SkinnyRx↗ ($299) — gaps of $11 and then $10 a month, a $252 spread across a year between first and last. All-in figures, 10 mg basis, captured 2026-08-09.
Updated 2026-08-10 · figures captured 2026-08-09 · how we verify
The three records, one screen
IVIM Health: the record, condensed
On tirzepatide, the number that matters at IVIM Health is $278 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. Pricing steps with the dose here: from $208 at entry to $278 at the 10 mg basis. Multiply the wrong one of those by twelve and your budget is off by $840 a year, which is why every ranking on this site uses the larger number.
Inside that $278 sits a mandatory $75-a-month membership. We fold it in automatically — the medication-only figure the marketing may lead with is $203, and it is not a price anyone can actually pay, because the membership cannot be declined.
To place the number: #3 of 17 verified programs, with the floor $63/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $171 a month. A year at this figure: $3,336 monthly-billed.
Start with the load-bearing figure: $149 a month, all-in, is what IVIM Health charges for semaglutide at the 2.4 mg basis. The figure is quoted at maintenance without a separate teaser tier, which keeps the arithmetic honest by default.
Inside that $149 sits a mandatory $75-a-month membership. We fold it in automatically — the medication-only figure the marketing may lead with is $74, and it is not a price anyone can actually pay, because the membership cannot be declined.
Context for that figure: it ranks #3 of 20 in the verified semaglutide index — $16/month above the floor (Oak Longevity, $133) — and sits $200 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $1,788.
Operationally at IVIM Health: shipping included; commitment membership mandatory for duration; cancellation membership mandatory; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the IVIM Health page · visit IVIM Health ↗
Found: the record, condensed
On tirzepatide, the number that matters at Found is $289 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.
There is no membership line. $289 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.
To place the number: #6 of 17 verified programs, with the floor $74/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $160 a month. A year at this figure: $3,468 monthly-billed.
On semaglutide, the number that matters at Found is $289 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at Found is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.
The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.
Context for that figure: it ranks #15 of 20 in the verified semaglutide index — $156/month above the floor (Oak Longevity, $133) — and sits $60 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $3,468.
Operationally at Found: shipping included; commitment none month-to-month; prepaid terms for lowest rate; cancellation membership recurs; prepaid terms are paid up front; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Found page · visit Found ↗
SkinnyRx: the record, condensed
Start with the load-bearing figure: $299 a month, all-in, is what SkinnyRx charges for tirzepatide at the 10 mg basis. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.
There is no membership line. $299 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.
To place the number: #7 of 17 verified programs, with the floor $84/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $150 a month. A year at this figure: $3,588 monthly-billed.
Start with the load-bearing figure: $199 a month, all-in, is what SkinnyRx charges for semaglutide at the 2.4 mg basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at SkinnyRx is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.
Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $199 is the whole subscription, which makes SkinnyRx unusually easy to compare and unusually easy to leave.
Context for that figure: it ranks #11 of 20 in the verified semaglutide index — $66/month above the floor (Oak Longevity, $133) — and sits $150 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $2,388.
Operationally at SkinnyRx: shipping included; commitment none; cancellation no membership on compounded programs; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the SkinnyRx page · visit SkinnyRx ↗
Prices, gaps, and what sits inside them
IVIM Health holds the low ground at $278 (its $75 membership already inside). Found follows at $289 (+$11/mo, $132/yr). SkinnyRx tops the trio at $299 (+$21/mo over the leader, $252/yr) — note its record’s watch-out below.
The semaglutide picture reshuffles nothing: IVIM Health $149 → SkinnyRx $199 → Found $289 — a reminder that molecule choice and provider choice are separate decisions, priced separately in the semaglutide index.
Who wins what
Cheapest month-to-month: IVIM Health ($278); cheapest 12-month path: IVIM Health ($3,336); simplest billing (no membership): Found and SkinnyRx; dose-flat structure: Found and SkinnyRx; cheapest semaglutide of the three: IVIM Health ($149).
Every winner above is a computation, not a placement; the pairwise pages carry the full duels: IVIM Health vs Found · IVIM Health vs SkinnyRx · Found vs SkinnyRx.
Everything besides the three prices
Memberships: IVIM Health $75/mo (inside its figure); Found none; SkinnyRx none. Structures: IVIM Health step/tiered; Found dose-flat; SkinnyRx dose-flat. Pharmacies: IVIM Health not named; Found not named; SkinnyRx not named. States: IVIM Health — not published; Found — most states; SkinnyRx — not published. Exit terms: IVIM Health — membership mandatory; Found — membership recurs; prepaid terms are paid up front; SkinnyRx — no membership on compounded programs.
The census reading: where all three match on an axis, that axis cannot break the tie and the price column rules; where they split — a membership here, an unnamed pharmacy there — the split is usually worth more than a small price gap, because structure is what you live with after month one. Evidence for all three: IVIM Health source-verified (2026-08-05); Found third-party reported (2026-08-05); SkinnyRx source-verified (2026-08-05).
The trio on semaglutide, across time
3 mo: IVIM Health $447 vs SkinnyRx $597 vs Found $867 6 mo: IVIM Health $894 vs SkinnyRx $1,194 vs Found $1,734 12 mo: IVIM Health $1,788 vs SkinnyRx $2,388 vs Found $3,468 — monthly-billed totals; prepaid paths where published appear on each provider page.
The trio, annualized
IVIM Health: $3,336/yr monthly-billed; Found: $3,468/yr monthly-billed; SkinnyRx: $3,588/yr monthly-billed. Across two years at monthly billing the first-to-last spread widens to $504 — the horizon at which structure (prepaid ladders, flat pricing, membership drag) matters more than the sticker.
The elimination read
A three-way choice is really two eliminations, so run them in order. Eliminate SkinnyRx first unless it names its edge: at $299 it carries a $21/month premium over the floor of this trio — $252 a year, about 0.9 extra months of therapy at IVIM Health’s rate — and a premium that size must point at a specific line in its record (its particular program design) or it is decoration. Then interrogate Found’s middle ground: its dose-flat structure removes titration repricing; if that specific thing is on your personal ledger, the $11/month over the floor can be rational — if not, the middle is where budgets go to leak. What survives is IVIM Health at $278, which wins by default rather than by argument — exactly how a price index should crown things — subject to the two checks no ranking can run for you: your state at intake, and your prescriber on the medication itself.
The same trio on best published rate: IVIM Health $278 → Found $289 → SkinnyRx $299 — all three price month-to-month only at capture. Short-horizon totals, monthly-billed: 3 months — IVIM Health $834, Found $867, SkinnyRx $897; 6 months — IVIM Health $1,668, Found $1,734, SkinnyRx $1,794. 0 of the three publish a prepaid path below their own monthly billing; the twelve- and twenty-four-month table below carries those, labeled.
The record-quality read, scored on the five checkable disclosures this index tracks (maintenance price, named pharmacy, published states, published cancellation terms, source-verified capture): IVIM Health 4/5, Found 3/5, SkinnyRx 4/5. IVIM Health discloses the most and Found the least, and in this market disclosure predicts disclosure — the axis where a program goes quiet is reliably where its checkout surprises live. The three match on every disclosure axis, which is rare and worth noting in their favor collectively. Scores recompute from the public records like everything else here.
Read as a decision: start from IVIM Health and make the other two argue upward. Found’s case is its structure; SkinnyRx’s case must be worth $252 a year in named features — the honest unit being months of medication (0.9 of them at the floor rate). The pairwise pages above hold each argument in full, and the calculator holds your version of it.
Frequently asked
Which is cheapest: Found, IVIM Health, or SkinnyRx?
IVIM Health, at $278/month all-in tirzepatide — $11 under Found and $21 under SkinnyRx; on semaglutide the cheapest of the three is IVIM Health at $149. Captured 2026-08-09.
Which of the three is best over a full year?
IVIM Health’s best path prices twelve months at $3,336; monthly-billed years run IVIM Health $3,336, Found $3,468, SkinnyRx $3,588.
Are these rankings paid or editorial?
Neither — they are sorts of the public dataset on the all-in maintenance basis, regenerated on every data change; the methodology page defines the basis and the JSON lets you recompute every figure here.